Literature DB >> 24271123

Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration - effect of lipid composition.

K Hirano1, C A Hunt, A Strubbe, R D Macgregor.   

Abstract

Tumor cells often metastasize through lymphatic channels. It follows that localization of antitumor agents in the lymphatics may be therapeutically beneficial. This study determines the extent to which lipid composition controls lymphatic transport of a model compound ((14)C-sucrose) in liposomes following intraperitoneal administration in rats. All liposomes tested had mean diameters of approximately 0.2 µm. Liposomes were administerd to thoracic duct cannulated rats, and (14)C was quantified in thoracic lymph, several lymph nodes, blood, urine, and peritoneal wash. Changing liposome composition altered the rate of absorption of (14)C from the peritoneal cavity, stability in biological fluids, and the relative ability of liposomes to be retained by lymph nodes. Stability in biological fluids (plasma and lymph) appeared to be a reasonable predictor of observed lymph node recovery. Direct measures of lymph node level alone were poor measures of the ability of liposomes to function as prototypal lymphatic drug carriers. Neutral liposomes were better at reaching the general circulation following absorption from the peritoneal cavity.

Entities:  

Year:  1985        PMID: 24271123     DOI: 10.1023/A:1016337500364

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Liposomes as vehicles for the local release of drugs.

Authors:  A W Segal; G Gregoriadis; C D Black
Journal:  Clin Sci Mol Med       Date:  1975-08

2.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

3.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Authors:  R L Dedrick; C E Myers; P M Bungay; V T DeVita
Journal:  Cancer Treat Rep       Date:  1978-01

4.  Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats.

Authors:  R J Parker; E R Priester; S M Sieber
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

5.  Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats.

Authors:  T M Allen; J M Everest
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

6.  Liposomes disposition in vivo. V. Liposome stability in plasma and implications for drug carrier function.

Authors:  C A Hunt
Journal:  Biochim Biophys Acta       Date:  1982-12-17

7.  Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.

Authors:  R F Ozols; G Y Locker; J H Doroshow; K R Grotzinger; C E Myers; R I Fisher; R C Young
Journal:  Cancer Treat Rep       Date:  1979-02

8.  Peritoneal lymphatic uptake of fibrinogen and erythrocytes in the rat.

Authors:  M F Flessner; R J Parker; S M Sieber
Journal:  Am J Physiol       Date:  1983-01

9.  Carrier activity of sonicated small liposomes containing melphalan to regional lymph nodes of rats.

Authors:  J Khato; A A del Campo; S M Sieber
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

10.  Intralymphatic administration of liposome-encapsulated drugs to mice: possibility for suppression of the growth of tumor metastases in the lymph nodes.

Authors:  V I Kaledin; N A Matienko; V P Nikolin; Y V Gruntenko; V G Budker
Journal:  J Natl Cancer Inst       Date:  1981-05       Impact factor: 13.506

View more
  7 in total

1.  The Basic Study of Liposome in Temperature-Sensitive Gel at Body Temperature for Treatment of Peritoneal Dissemination.

Authors:  Ikumi Sugiyama; Kaana Ando; Yasuyuki Sadzuka
Journal:  Gels       Date:  2022-04-20

2.  Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration.

Authors:  Xi Zhan; Kenny K Tran; Hong Shen
Journal:  Mol Pharm       Date:  2012-11-20       Impact factor: 4.939

3.  Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.

Authors:  A Sharma; N L Straubinger; R M Straubinger
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

4.  Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats.

Authors:  P Maincent; P Thouvenot; C Amicabile; M Hoffman; J Kreuter; P Couvreur; J P Devissaguet
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

5.  Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer.

Authors:  Yu Hang; Siyuan Tang; Weimin Tang; David Větvička; Chuhan Zhang; Ying Xie; Fei Yu; Ao Yu; Diptesh Sil; Jing Li; Rakesh K Singh; David Oupický
Journal:  J Control Release       Date:  2021-03-25       Impact factor: 9.776

Review 6.  Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent.

Authors:  L De Smet; W Ceelen; J P Remon; C Vervaet
Journal:  ScientificWorldJournal       Date:  2013-03-25

7.  Numerical modeling of high-intensity focused ultrasound-mediated intraperitoneal delivery of thermosensitive liposomal doxorubicin for cancer chemotherapy.

Authors:  Mohsen Rezaeian; Amir Sedaghatkish; M Soltani
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.